



1631

# TRANSMITTAL FORM

Application Serial Number	09/922,251
Filing Date	August 3, 2001
First Named Inventor	Steitz
Group Art Unit	1631
Examiner Name	Not Yet Assigned
Attorney Docket No.	RIB-001CP
Patent No.	Not applicable
Issue Date	Not applicable

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in duplicate)
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets _____]	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Associate Power of Attorney	<input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations (A4-A14, B4-B9 and C101-C115)	<input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Amendment After Allowance	
<input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	

RECEIVED  
APR

TECHNOLOGY  
1600/2000

## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,  
  
Duncan A. Greenhalgh  
Attorney for Applicants  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

Date: April 15, 2003  
Reg. No. 38,678  
Tel. No.: (617) 248-7317  
Fax No.: (617) 248-7100



PATENT  
Attorney Docket No.: RIB-001CP  
(7995/3)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Steitz *et al.*  
SERIAL NO.: 09/922,251 GROUP NO.: 1631  
FILING DATE: August 3, 2001 EXAMINER: Not yet assigned  
TITLE: RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS  
INHIBITORS

RECEIVED  
APR 21 2003  
TECH CENTER 1600/2900

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on this 15<sup>th</sup> day of April, 2003.

  
\_\_\_\_\_  
Nicole Deane

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith are:

1. Transmittal Form (1 pg.);
2. Supplemental Information Disclosure Statement (2 pgs.);
3. Form PTO-1449 (2 pgs.);
4. Copies of Documents Cited as A4-A14, B4-B9 and C101-C115; and
5. Return Receipt Postcard.

2594691



PATENT  
Attorney Docket No.: RIB-001CP  
(7995/3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Steitz *et al.*  
SERIAL NO.: 09/922,251 GROUP NO.: 1631  
FILING DATE: August 3, 2001 EXAMINER: Not yet assigned  
TITLE: Ribosome Structure and Protein Synthesis Inhibitors

Commissioner for Patents  
Washington, D.C. 20231

#20  
Plunkett  
7/22/03  
RECEIVED  
APR 21 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the published patent documents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the published patent documents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**

- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### STATEMENT


As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Date: April 15, 2003  
Reg. No.: 38,678

Tel. No.: (617) 248-7317  
Fax No.: (617) 248-7100

Respectfully submitted,



Duncan A. Greenhalgh  
Attorney for Applicants  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110



FORM PTO - 1449

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: RIB-001CP

APPLICANTS: Steitz *et al.*

SERIAL NO.: 09/922,251

FILING DATE: August 3, 2001

GROUP: 1631

**RECEIVED**  
APR 21 2003  
TECH CENTER 1600/2800

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A4	5,693,791	12/02/97	Truett			04/11/95
	A5	5,866,549	02/02/99	Or <i>et al.</i>			07/03/97
	A6	5,336,768	08/09/94	Albrecht <i>et al.</i>			05/24/88
	A7	5,281,703	01/25/94	White <i>et al.</i>			05/07/93
	A8	5,180,719	01/19/93	White <i>et al.</i>			04/29/91
	A9	6,468,979 B1	10/22/02	Pellacini <i>et al.</i>			07/27/99
	A10	6,437,119 B1	08/20/02	Truett			07/17/00
	A11	5,905,144	05/18/99	Truett			09/15/97
	A12	5,466,681	11/14/95	Krivan <i>et al.</i>			01/12/94
	A13	6,380,356 B1	04/30/02	Griffin <i>et al.</i>			12/07/99
	A14	6,446,032 B1	09/03/02	Schimmel			08/14/92

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	B4	EP 1 186 614 A2	03/13/02	EP			07/16/01		
	B5	EP 1 188 769 A2	03/20/02	EP			08/09/01		
	B6	WO 00/32619	06/08/00	WO			11/24/99		
	B7	WO 95/07271	03/16/95	WO			08/16/94		
	B8	WO 96/18633	06/20/96	WO			12/07/95		
	B9	WO 97/35195	09/25/97	WO			03/19/97		

EXAMINER

DATE CONSIDERED



FORM PTO - 1449		ATTORNEY DOCKET NO.: RIB-001CP
SUPPLEMENTAL INFORMATION		APPLICANTS: Steitz <i>et al.</i>
DISCLOSURE STATEMENT		SERIAL NO.: 09/922,251
		FILING DATE: August 3, 2001
		GROUP: 1631
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)	
	C101	Fourmy <i>et al.</i> (1996) "Structure of the A Site of <i>Escherichia coli</i> 16S Ribosomal RNA Complexed with an Aminoglycoside Antibiotic" <u>Science</u> 274(5291):1367-1371
	C102	Hermann <i>et al.</i> (1999) "Docking of Cationic Antibiotics to Negatively Charged Pockets in RNA Folds" <u>J. Med. Chem.</u> 42(7):1250-1261
	C103	Ioannou <i>et al.</i> (1998) "Kinetics of Inhibition of Rabbit Reticulocyte Peptidyltransferase by Anisomycin and Sparsomycin" <u>Molecular Pharmacology</u> 53(6):1089-1096
	C104	Kirillov <i>et al.</i> (1999) "Peptidyl Transferase Antibiotics Perturb the Relative Positioning of the 3'-Terminal Adenosine of P/P'-Site-Bound tRNA and 23S rRNA in the Ribosome" <u>RNA</u> 5(8):1003-1013
	C105	Spickler <i>et al.</i> (1997) "Streptomycin Binds to the Decoding Center of 16 S Ribosomal RNA" <u>J. Mol. Biol.</u> 273(3):586-599
	C106	Wong <i>et al.</i> (1998) "Specificity of Aminoglycoside Antibiotics for the A-Site of the Decoding Region of Ribosomal RNA" <u>Chemistry &amp; Biology</u> 5(7):397-406
	C107	European Search Report for Application No. 02255442.2 dated March 6, 2003
	C108	Hanessian <i>et al.</i> (1984) " "Quantamycin": A Computer-Simulated New-Generation Inhibitor of Bacterial Ribosomal Binding" <u>Journal American Chemical Society</u> 106:6114-6115
	C109	Vince <i>et al.</i> (1975) "Chloramphenicol Binding Site with Analogues of Chloramphenicol and Puromycin" <u>Antimicrobial Agents and Chemotherapy</u> 8(4):439-443
	C110	Shuker <i>et al.</i> (1996) "Discovering High-Affinity Ligands for Proteins: SAR by NMR" <u>Science</u> 274(5292):1531-1541
	C111	Hecker <i>et al.</i> (1993) "Application of Hygromycin A Structure Activity Relationships to the Antibiotic A201A" <u>Bioorganic &amp; Medicinal Chemistry Letters</u> 3(2):295-298
	C112	Wang <i>et al.</i> (1997) "Dimeric Aminoglycosides: Design, Synthesis and RNA Binding" <u>Bioorganic &amp; Medicinal Chemistry Letters</u> 7(14):1951-1956
	C113	Holmes <i>et al.</i> (1993) "Novel Dimeric Penicillin Derived Inhibitors of HIV-1 Proteinase: Interaction with the Catalytic Aspartates" <u>Bioorganic &amp; Medicinal Chemistry Letters</u> 3(4):503-508
	C114	Rao <i>et al.</i> (1997) "Tight Binding of a Dimeric Derivative of Vancomycin with Dimeric L-Lys-D-Ala-D-Ala" <u>J. Am. Chem. Soc.</u> 119:10286-10290
	C115	Tanihara <i>et al.</i> (1998) "Thrombin-Sensitive Peptide Linkers for Biological Signal-Responsive Drug Release Systems" <u>Peptides</u> 19(3):421-425
EXAMINER		DATE CONSIDERED

RECEIVED  
APR 21 2003  
TECH CENTER 1600/2900